Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebamipide + Omeprazole for Gastric Ulcer
NCT01150162Phase 3Completed
- Sponsor
- Otsuka Holdings
- Start
- Oct 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rebamipide in gastric ulcer (2 arms), sponsored by Otsuka Holdings. Primary endpoints: Healing rates for gastric ulcer patients via endoscopic examination at 12 weeks and Improvement or absence of gastric ulcer associated symptoms at 12 weeks. Started Oct 2010; status: completed.
02
Drugs
rebamipide
03
Conditions
gastric ulcer
Beyond the preview
Go deeper on NCT01150162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01150162.